519 related articles for article (PubMed ID: 22512637)
1. IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H; Husain SR; Puri RK
Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
[TBL] [Abstract][Full Text] [Related]
2. A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.
Nakashima H; Terabe M; Berzofsky JA; Husain SR; Puri RK
J Immunol; 2011 Nov; 187(10):4935-46. PubMed ID: 22013118
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
5. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
Gjerstorff MF; Burns J; Ditzel HJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.
Nakashima H; Fujisawa T; Husain SR; Puri RK
J Transl Med; 2010 Nov; 8():116. PubMed ID: 21067607
[TBL] [Abstract][Full Text] [Related]
7. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis.
Fujisawa T; Joshi B; Nakajima A; Puri RK
Cancer Res; 2009 Nov; 69(22):8678-85. PubMed ID: 19887609
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
10. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.
Mintz A; Gibo DM; Madhankumar AB; Cladel NM; Christensen ND; Debinski W
Cancer Biother Radiopharm; 2008 Oct; 23(5):581-9. PubMed ID: 18976118
[TBL] [Abstract][Full Text] [Related]
11. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract][Full Text] [Related]
13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
16. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
17. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
18. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
[TBL] [Abstract][Full Text] [Related]
19. Tumor vaccine: current trends in antigen specific immunotherapy.
Baral R
Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
